Ceapro has presented results from a pre-clinical study of inhalable yeast beta glucans processed with the company’s pressurized gas expanded (PGX) technology at ATS, the company said. The study, which was conducted in collaboration with McMaster University, evaluated the aerosolization characteristics of inhaled PGX-processed yeast beta glucans (PGX-YBG) and the ability of the PGX-YBG to reprogram macrophages within mouse lungs. Ceapro is developing PGX-YBG for the treatment of interstitial lung diseases.
Ceapro President and CEO Gilles Gagnon commented, “Our initial hypothesis was that PGX-YBG particles could be safely delivered into human lungs. These results provide encouraging confirmation of that hypothesis and bolster our confidence for the continued development toward a potential treatment option for IPF. This evidence, along with the latest in-vitro and in-vivo data, provides the validation that PGX-YBG holds significant potential as a therapeutic strategy for a broad spectrum of fibrotic endpoint lung diseases such as COVID-19 related lung fibrosis and IPF. With these results now in hand, we are evaluating our pre-planned go/no-go decision for advancement of this program into a Phase 1 clinical trial and expect to provide updates in Q3 of this year.”
McMaster Professor Martin Kolb said, “Until now, we have had very limited treatment options for fibrotic lung disease since approved medications can only slow down the progression of the disease. We are very encouraged by the results from this study showing that PGX-YBG has the ability of reprogramming macrophages to prevent fibrogenesis in mice. If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics.”
Read the Ceapro press release.
